Value Sense
RPRX
Royalty Pharma plc (RPRX)
Last Price$33.90.6%
Market Cap$15.2B
LTM P/E
17.7x
EPS growth
61.4%
PEGY
0.3x
Peter Lynch Fair Value
$122.1
Undervalued (Peter Lynch formula)
260.8%
Stock quality
6/10
Good
RPRX
is 430.9% undervalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

RPRX Peter Lynch Fair Value

Peter Lynch Fair Value Assumptions

as of Mar 10, 2025
LTM P/E
17.7x
EPS growth
61.4%
Dividend Yield
2.5%
PEGY
0.3x
Last share price
$33.9
Peter Lynch Fair Value
$122.1
260.8% undervalued

Peter Lynch Fair Value Calculation

PEGY
0.3x
=
LTM P/E
17.7x
/
(
EPS growth
61.36%
+
Dividend yield
2.48%
)
Peter Lynch
Fair Value
$122.1
=
Last share price
$33.9
/
PEGY
0.3x

Best stock ideas on the market right now

With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks

Low P/E stocks

Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.

3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%

RPRX EPS growth & Dividend Yield

Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
EPS growth
Dividend Yield

RPRX vs Peer Set: Peter Lynch Fair Value Comparison

General

PETER LYNCH FAIR VALUE

Financial metrics

Company name

Undervaluation / Overvaluation

Revenue growth

EBITDA margin

Net Income margin

Royalty Pharma plc logo
Royalty Pharma plcRPRX
260.8%
(3.8%)
(43.7%)
37.9%
Median Peer Set
23.0%
(56.5%)
0.8%
BeiGene, Ltd. logo
BeiGene, Ltd.BGNE
3,245.7%
73.7%
(56.5%)
(35.9%)
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.REGN
(45.9%)
8.3%
10.4%
31.1%
United Therapeutics Corporation logo
United Therapeutics CorporationUTHR
(50.9%)
23.6%
25.7%
41.5%
Incyte Corporation logo
Incyte CorporationINCY
27.3%
14.8%
(94.0%)
0.8%
Novo Nordisk A/S logo
Novo Nordisk A/SNVO
(18.5%)
24.9%
142.8%
34.8%
Summit Therapeutics Inc. logo
Summit Therapeutics Inc.SMMT
(137.6%)
N/A
(68.7%)
N/A
BioNTech SE logo
BioNTech SEBNTX
N/A
(77.4%)
(89.7%)
24.4%
argenx SE logo
argenx SEARGX
N/A
198.6%
(60.5%)
(24.1%)
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.ALNY
N/A
23.0%
(38.6%)
(12.4%)
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals IncorporatedVRTX
N/A
11.7%
N/A
(4.9%)

Explore more intrinsic value tools hub for RPRX

Margin of safety
Ben Graham Fair Value
Earnings growth model
Discount rate
Peter Lynch charts
Reverse DCF
Earnings Power Value
Intrinsic Value
DCF value calculator
Relative Value

FAQ

What is Royalty Pharma plc fair value by Peter Lynch formula?

As of Mar 03, 2025, Royalty Pharma plc's fair value using the Peter Lynch formula is $122.1 per share. The current price of $33.9 suggests Royalty Pharma plc may be undervalued by this metric.

What is Royalty Pharma plc Price to Earnings (P/E) ratio?

As of Mar 03, 2025, Royalty Pharma plc's P/E ratio is 17.7x. This is calculated by dividing the current share price of $33.9 by the Earnings per Share (EPS) for the trailing twelve months, which is $2.3. The P/E ratio indicates how much investors are willing to pay for each dollar of earnings.

What is Royalty Pharma plc earnings per share (EPS)?

Royalty Pharma plc earnings per share (EPS) for the twelve months ending Mar 03, 2025, was $2.3, a 61.4% growth year-over-year.